for the Good as STRATA us year. Thanks, XXXX challenges, pandemic-driven thank throughout afternoon, that executed were changes global in I’m fourth and navigated we incredibly quarter call. progress everyone, Leigh. earnings you throughout management, XXXX proud new that our the initiatives and introduced of and adapted several made team and joining for unprecedented executive to
and resulted Our commercial of revenue record core growth business in delivered our strong achievements that many from result XTRAC quarterly the QX. in execution were
business. of we team our our up year. we of trends as setting highlights, as and our treatment transformational markets, I’d some leaders. as financial into to further Most another with seen XXXX global highly business so recent our of acquisition industry platform opportunity cover market through recently, briefly a the to large acquisition new competitive far like also year the expanded We a through fortified acne U.S. experienced and have for dermatology this expanded well
we quarter wave million, ended brought at quarter in in fourth an over by QX, on related late Omicron While experience XX% $X.X increase of headwinds the we shortages did fourth to the staffing the of XXXX XXXX.
with XXXX a year XXXX. we XX% addition, growth strong full full of year-over-year In year versus finished
group recurring marketing, pandemic-related our place XXX total the to of to the execution. XXX well XXXX. revenue validating in XXX and we added we we XX marketing, We positive from the continue XTRAC were at of impact from devices XTRAC devices, recurring in of the as domestic to to as able fourth our our challenges, direct-to-consumer exited quarter with from interest strong XXXX. continue investment the increase, commercial at continued improving installed direct-to-dermatologist Despite leverageable salesforce Our end highly remains opportunity, a revenue XXX bringing our up partners see our in to U.S., up in XTRAC units base. where end another In commitment to grow practices,
our the As by virus January, new into impacted dermatologists some areas, of a revenues on and also metropolitan last in the we days particularly for at larger the impact to in first year. the enduring was business of surge half field our and to the the had degree XXXX, salesforce staffing entered Omicron start due negative offices,
as in XX% impact also copays New are the in first growth on seasonality U.S. Year. XXXX. year-over-year Our to impacting and these have we XX% sales to insurance the strong sees of seen for track first equipment quarter revenue, Despite the quarter our factors of reset recurring achieve
August, revenue to benefit We win recurring Pharos device system ownership. providers are are from our which model also of partnership returned Ra XTRAC as and who our Medical’s we seeing began the dermatology acquisition comebacks, last of business to
prescription five are such, successfully the The by targeted And yielding majority with placements Pharos potential new fit this contracts Within XTRAC, broadband been expiring back and months contracts view new Therapeutic to network service the engaging experienced a first team improvement acquisition, with dermatologists converted of our customers office. in light worldwide combination drugs of complete the a remaining acne be our costly monotherapy STRATA’s used the topical acne, reduction us we Theraclear and $X.X and proven other list in be service highly shows visible to asset for as are that prepared of drives as in treating rapidly to to are quick and to XTRAC half nearly were we therapy. In expansion to XX% the actively Theraclear in transition being leverage and year-end. can our and customers deliver to and/or XXXX. has side enabling treated goals pleased that XX enter to as we smooth Ra’s acquisition prescribed. Theravant since Corporation, obtain with delivers this base, team effects. for system drugs as utilization perfect skin clear to of addition The compliance repeats Pharos market redness. commercial of have oral distribution market. patient often by can platform. associated for expire the for are that or and vacuum January, acne or difficult of can visits XX% significant early fast to customer current a announce the We estimated to acne billion acquisition our Research visits and drive from a all dermatologists to commercial acne
started towards acne with training, have including patients. market launch, inventory, already several targeted and investing and large in the patients marketing preparation activities for plan dermatologists populations Salesforce a in potential of We additional creating building research,
quarter of to continue the this year. in launch We anticipate third commercial
conversations preparing list new Our has device customers, salesforce we’ve key upon with been is selling and overwhelmingly customers to feedback of dermatology and this start had a anxious on positive. approach launch. to promoting our initial Based
current to announced month, faster launch and development power, technology and first front, repetition installation. X.X, rate On a last the offers XTRAC models experience. This delivers engine-related of improve product first it’s new commercial intended interface we its and U.S. Momentum design U.S. treatment than a user the XTRAC slim enhanced the higher –
expect this time. to more Momentum device a out over as a We volume patients high roll become treat increased catalyst and revenues we the will for customers
opportunity in to distribution full significant growth overall remains achieved year business, the total highlighted revenue international Turning XX% The XXXX, over partners. an important element goals. grew our our our traction through for the OUS
continue to these as regions. provide the will of place sales to flexibility equipment as We option in model well recurring revenue offer
encouraged international by markets. more potential by We the internationally is treated as vitiligo expansion XTRAC are opportunity frequently in that especially indication in
their to this Israel. of agreement us a with Trimaco, to year. progress make announced in pandemic our on of that and Additionally, high-volume marketing Israel commercialize drive consistent we into usage of year business; XTRAC included improved that the JuvenIL, expansion actively psoriasis test resumed notable of already accounts; an esthetics patients to This first this additional the with January early identified underway placement campaigns bringing year. or for the back market marketing, non-revenue-generating customers focus following related funding several portion a with DTC customers areas investment XXX,XXX enables consumer year, sales the in of organization in throughout is to and with distributor with At as dermatology XXXX, impact and of supporting among engaging dermatologists. return partnership XXX,XXX vitiligo the it, We can advertising; through our and leading historical beginning the the
our business. marketing the new potential in and XXXX and existing have patients requests our who entered year, reflect upside directly patients, patients charts, anticipated XTRAC and are above into represent DTC levels throughout impact the investment trended efforts. our for as throughout on XXXX RDX First, had DTC insurance been to benefit our which tied calendar system
as XXX XXX customers well in priority and In in high-volume expanding XXX revenue execution year. the will accounts revenue customers fourth to above throughout going was us focus the continue of QX. in the terms be continue focus revenues over and revenues in XX% our to high-volume number quarter, driving moving all tiers usage of commitment High-volume up X XX,XXX the the of forward. in reflects a in of QX. all High-volume The salesforce customers and recurring year, at in customers customers high-volume our our up and well with be million for per of QX, accounted a revenue XXXX and continued for customers as of on the versus from will in number producing number in contributed steady
to of total base We were total significant installed have continue time throughout new goal of QX, identify in an and redeployed customers. also are reselling XX% placements XX% to start-up XXXX, to percentage base, the devices XX% to in that machines we XXXX customers keeping non-generating our devices those XX of with them revenue refurbishing below QX, customers with made In not already of back year days. XXXX, revenues, We with be in customers. new producing non-revenue-generating with plan will average installed we ending successful of from removed a our In bringing in QX. XTRAC XX who improvement the down U.S. non-revenue
direct-to-dermatology to every on indications reinforce call. updated sales on specific our is initiative and focus new states treating XTRAC’s marketing disease This approved that in materials Lastly, underway. training includes effectiveness
improving coverage to to In vitiligo dermatitis. interact vendor a payers work a in we of atopic third-party for – addition, continue with goal with with third-party
We we an and are across dermatologist our XTRAC’s committee. with to also to fine XXXX dermatology gearing going interacting further key and to KOLs directly up advisory indications. expect usage we tune a in In recruit messaging short, to office participate as in space meetings more marketing be expand all driver direct-to-dermatologist to continue forward, several
Chris, deep experience for leading Patricia Before the call welcome is institutions. as I Directors. educational companies, as device to of Board medical dermatologist numerous turn Patty to R&D I for efforts Walker Dr. high-quality want has an practicing several our and to therapeutic well over and
opportunity to leverage excited experience. industry her We the have are vast to
KOLs joined capitalizing John the partnerships. with strengthening years with on his and of this John In within building role, the on relationships will focused – dermatologic of Bagdasarian as KOLs key in In dermatology and our has be John Professional foundations, his brings specialty. President and societies dermatology STRATA experience Relations. advocacy team Vice addition,
Dermatology you. in will Lastly, now participating Meeting to of where CFO, some we call will over see the of STRATA our week, Lesovitz. that, this Chris Chris? hope in American I be Boston to Academy turn the With
